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Abstract Evaluation of human epidermal growth factor recep-
tor 2 (HER2) immunohistochemistry (IHC) is subject to inter-
observer variation and lack of reproducibility. Digital image
analysis (DIA) has been shown to improve the consistency
and accuracy of the evaluation and its use is encouraged in
current testing guidelines. We studied whether digital image
analysis using a free software application (ImmunoMembrane)
can assist in interpreting HER2 IHC in equivocal 2+ cases. We
also compared digital photomicrographs with whole-slide im-
ages (WSI) as material for ImmunoMembrane DIA. We stained
750 surgical resection specimens of invasive breast cancers
immunohistochemically for HER2 and analysed staining with
ImmunoMembrane. The ImmunoMembrane DIA scores were
compared with the originally responsible pathologists’ visual
scores, a researcher’s visual scores and in situ hybridisation
(ISH) results. The originally responsible pathologists reported
9.1 % positive 3+ IHC scores, for the researcher this was 8.4 %
and for ImmunoMembrane 9.5 %. Equivocal 2+ scores were
34 % for the pathologists, 43.7 % for the researcher and 10.1 %
for ImmunoMembrane. Negative 0/1+ scores were 57.6 % for
the pathologists, 46.8 % for the researcher and 80.8 % for
ImmunoMembrane. There were six false positive cases, which
were classified as 3+ by ImmunoMembrane and negative by
ISH. Six cases were false negative defined as 0/1+ by IHC
and positive by ISH. ImmunoMembrane DIA using digital pho-
tomicrographs and WSI showed almost perfect agreement. In
conclusion, digital image analysis by ImmunoMembrane can
help to resolve a majority of equivocal 2+ cases in HER2
IHC, which reduces the need for ISH testing.
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Introduction
The human epidermal growth factor receptor 2 (HER2,
ERBB2) oncogene protein is overexpressed in approximately
15 % of primary breast cancers [1–4]. The HER2 status of a
tumour provides both prognostic and predictive information
and is required for patients to qualify for chemotherapy with
anti-HER2 drugs such as trastuzumab, lapatinib and
pertuzumab [5, 6]. HER2 testing is standard of care in the
histopathological diagnosis of breast and gastric cancers and
is done mostly by immunohistochemistry (IHC) and in situ
hybridisation (ISH) [7, 8].
The optimal strategy for HER2 testing has been under de-
bate for over a decade and there is no consensus as to which
testing algorithm is the “gold standard”. ISH (both fluorescent
and bright-field, to detect HER2 gene amplification) is gener-
ally considered accurate and reliable although high reagent
costs and labour-intensiveness limit its use in most laborato-
ries to a secondary test to confirm equivocal immunohisto-
chemistry results [7, 9].
HER2 immunohistochemistry is straightforward and can
be performed in all modern diagnostic pathology laboratories.
Several reagent kits, such as HercepTest™ (Dako, Denmark),
PATHWAY™ (Ventana Medical Systems) and Oracle™
(Leica Biosystems) approved for clinical use by the U.S. Food
and Drug Administration (FDA), have been analytically
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validated and can be used in existing automated immunostain-
ing devices. However, evaluation of the HER2-stained slides
is subject to substantial interobserver variation and lack of
reproducibility [7]. In order to improve the accuracy of
HER2 testing, the American Society of Clinical Oncology
and the College of American Pathologists published [7] and
subsequently updated [10] guideline recommendations for de-
termining HER2 status of breast cancer (ASCO/CAP guide-
lines). According to current recommendations, equivocal re-
sults by IHC (staining of 2+ in the four-tier scale of 0 to 3+)
require additional confirmation by a validated assay for HER2
gene amplification [10].
Some studies report false scores in up to 14 % of cases [11,
12]. When viewing hundreds of slides (e.g. for a scientific
study), most pathologists find it relatively easy to maintain a
reproducible visual scale for their 0/1+, 2+ and 3+ scores,
whereas in a diagnostic pathology setting, many general pa-
thologists review only a small number of breast cancer cases
per week. A pathologist might not see a true 2+ case in weeks
to months, making it difficult to score borderline cases repro-
ducibly. While an incorrect HER2 score must be avoided,
most pathologists stay on the safe side, give a 2+ score and
submit the case for ISH testing. This reduces the cost- and
time-effectiveness of the two-step testing algorithm and some
authors argue for using FISH rather than IHC as the primary
assay for HER2 testing [13].
Digital image analysis (DIA) has been shown to improve the
consistency and accuracy of HER2 evaluation by IHC [14, 15]
and its use is encouraged in the ASCO/CAP guidelines for
cases with 1–2+ IHC staining [10]. We have previously intro-
duced the ImmunoMembrane software for digital image anal-
ysis of HER2 IHC using photomicrographs [16].
ImmunoMembrane (http://jvsmicroscope.uta.fi/software) is
both a free web application and an open-source plug-in for
the public domain image analysis tool ImageJ [17]. Further-
more, ImmunoMembrane has been introduced recently in a
web-based whole-slide image viewing system (JVSwebserver,
Jilab Inc., Tampere, Finland) which allows its use directly on
whole-slide images (WSI). ImmunoMembrane analyses the
completeness and intensity of the cell membrane staining reac-
tion, based on the IHC interpretation criteria of the ASCO/CAP
guidelines [7, 10]. This approach of analysing the anatomical
localisation of the staining reaction rather than just the immu-
noreaction intensity has been shown to correlate well with gene
amplification in HER2 diagnostics [18]. Similar image analysis
applications of HER2 have been described by both academic
research groups [15, 19–22] and commercial vendors
(reviewed elsewhere [23, 24]).
We conducted the current study to test whether
ImmunoMembrane can assist in interpreting the HER2 status
of cases visually classified as equivocal (2+) by IHC. We also
investigated the agreement between digital photomicrographs
and WSI as material for ImmunoMembrane DIA.
Materials and methods
A database search was conducted at the Department of Pathol-
ogy, Helsinki University Central Hospital, Finland, in order to
identify invasive breast cancer cases tested for HER2 from the
period of 1 January 2010 to 1 July 2011, resulting in 1249
cases. The slides for the corresponding surgical resection
specimens were retrieved from the archives, and starting from
the earliest case, 750 consecutive cases (one slide per case)
were included in the study. The 750 cases represented the
period of 1 January 2010 through 23 May 2011, in which
period 1186 breast cancer cases were histologically diag-
nosed. The missing 436 cases were not found in the archives
at the time of retrieval and were distributed along the whole
period of time taken for the study. The largest number of
consecutive cases missing was 28, representing a period of
14 days. The specimens had been routinely fixed for a period
of 24–48 h in neutral formalin and embedded in paraffin.
Immunohistochemistry had been performed according to
the manufacturer’s instructions using the BenchMark XT au-
tomated staining system (Ventana Medical Systems, Tucson,
AZ) with PATHWAY anti-HER2/neu (4B5) rabbit monoclo-
nal antibody at a dilution of 6 μg/ml and Ventana ultraView
Universal DAB Detection Kit (both Ventana Medical Sys-
tems). The slides were counterstained using Ventana Hema-
toxylin II (Ventana Medical Systems) as part of the automated
staining procedure.
The HER2 status of the specimens was established by im-
munohistochemical staining, and positive (3+) and equivocal
(2+) cases were further subjected to in situ hybridization to
classify them into positive and negative with regard to HER2
gene amplification. A total of 30 pathologists including resi-
dents and specialists scored the cases. Six of the specialists
were experienced breast pathologists and the residents rou-
tinely consulted senior pathologists before giving their scores.
In situ hybridization had been carried out in the Bench-
Mark XT automated staining system using the INFORM
HER2 DNA and the INFORM Chromosome 17 probes and
the ultraVIEW SISH Detection Kit (all Ventana Medical Sys-
tems) according to the manufacturer’s instructions. Consecu-
tive sections of the specimens were hybridised with the probes
for HER2 and chromosome 17, respectively, and the speci-
mens’ HER2 gene status was classified as amplified if the
ratio of HER2 to chromosome 17 was over 2.2. Both the
ISH and IHC assays have been subjected to external quality
assessment by the Nordic Immunohistochemical Quality Con-
trol [25].
For this study, the immunohistochemically stained slides
were digitally photomicrographed for image analysis and vi-
sually scored as positive (3+), equivocal (2+) or negative
(0/1+) by the researcher (HOH) without knowledge of the
original pathologist’s score. Before the photomicrography
and visual scoring, the researcher received training in HER2
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IHC evaluation from an experienced breast pathologist with
whom he also underwent interobserver testing on 35 consec-
utive cases from the study material. The cases were scored
visually as positive (3+), equivocal (2+) or negative (0/1+),
without knowledge of the original scores. This yielded a sub-
stantial interobserver agreement with a weighted kappa value
of 0.71 (95 % confidence interval 0.49–0.94) calculated using
linear weighting.
Digital photography was carried out with a standard Olym-
pus microscope equipped with an Mshot MC-30 3.3-mega-
pixel CCD microscope camera (Micro-shot Technology,
Guangzhou, China) using a 1X phototube. Aminimum of four
non-overlapping jpg images with a resolution of 2048 × 1536
pixels was captured per slide using a ×10 objective lens. The
photographed areas were chosen to represent the different
HER2 staining patterns of the cancer. In cases where the can-
cer was small and four non-overlapping images could not be
captured, the maximum number of non-overlapping images
was captured instead. In cases with a large cancer and a wide
range of staining patterns, more than four images were cap-
tured. A blank field image and an image of the on-slide pos-
itive control tissue (3+) were captured for each photography
session.
The images were analysed with the ImmunoMembrane
software (http://jvsmicroscope.uta.fi/immunomembrane/)
using the advanced mode. This permits the user to define
custom cutoff values for the IM score (0–20 points: 0–10
points for membrane completeness and 0–10 points for
membrane intensity) the software produces and uses to
classify staining into 0/1+, 2+ and 3+. We chose cutoff
values of 4 and 10 points (i.e. 0–3 points being classified as
0/1+, 4–9 points as 2+ and 10–20 points as 3+) based on our
previous experience and empirical testing. The blank field
image was used to correct for the microscope illumination
and colour balance whereas the positive control image was
used for reference contrast and intensity. A stage micrometre
was used to calculate the image scale in pixels per micrometre.
The statistical analyses were performed using MedCalc for
Windows, version 15.6.1 (MedCalc Software, Ostend,
Belgium).
Comparison of photomicrographs and WSI as material
for digital image analysis
The records of a HER2 diagnostics reference laboratory (Jilab
Inc., Tampere, Finland) were searched retrospectively from
May 2015 so as to identify invasive breast cancer cases
immunohistochemically stained for HER2. Ten consecutive
cases each of IHC staining patterns, 0/1+, 2+ and 3+ accord-
ing to the original pathologist’s report, were identified. The 30
cases, one glass slide per case, were scanned as whole-slide
images using the Objective Imaging Surveyor with Turboscan
(Objective Imaging Ltd., Cambridge, UK), using a ×20 Plan
Apo microscope objective (scanning resolution 0.23 μm per
pixel). Whole-slide images were stored as JPEG 2000 images.
The researcher analysed the virtual slides using
ImmunoMembrane directly in the whole-slide viewing inter-
face. This was done by defining a polygonal region of interest
(ROI) which was analysed by ImmunoMembrane included in
the WSI viewer software. A minimum of four areas were
analysed per WSI. The ImmunoMembrane DIA results were
compared to the original pathologists’ results which had been
obtained with the help of ImmunoMembrane using digital
photomicrographs. In all cases, the HER2 IHC score in the
original pathology report matched the ImmunoMembrane
score obtained using photomicrographs.
Results
In the original database search result of 1249 cases, 157 cases
(12.6 %) were positive by ISH and of the 750 case subset in our
current study 74 (9.9 %). In situ hybridisation had been per-
formed in 314 (41.9 %) cases (originally 2+ and 3+ by IHC).
The frequencies for a positive (3+) IHC staining for the original
pathologist, the researcher and ImmunoMembrane were 8.4 %
(63 cases), 9.5 % (71 cases) and 9.1 % (68 cases), respectively.
Equivocal (2+) staining was reported by the pathologist, re-
searcher and ImmunoMembrane in 34 % (255 cases), 43.7 %
(328 cases) and 10.1 % (76 cases), respectively. Negative stain-
ing (0/1+) showed, for the pathologist, researcher and
ImmunoMembrane, frequencies of 57.6 % (432 cases),
46.8 % (351 cases) and 80.8 % (606 cases), respectively. These
data are summarised in Table 1.
Of the 750 cases, 6 (0.8 %) were false positives in
ImmunoMembrane DIA, defined as cases 3+ positive by
IHC but negative by ISH. The corresponding number of false
positives was for the researcher 8 (1.1 %) and for the pathol-
ogist zero. Similarly, there were six (0.8 %) false negative
cases by ImmunoMembrane DIA (0/1+ negative by IHC
while positive by ISH). The number of false negatives was
zero for the researcher whereas it could not be defined for the
pathologist because the laboratory performed ISH only on
cases originally scored as 2+ or 3+ by IHC. A cross tabulation
comparing the IHC scores of the pathologist, researcher and
ImmunoMembrane DIAwith in situ hybridisation is presented
in Table 2. Examples of images from the ImmunoMembrane
analyses are shown in Fig. 1.
Analysis of outliers
We categorised the six false positive and six false nega-
tive cases (each representing 0.8 % of the total 750
cases) in ImmunoMembrane DIA into four categories:
truly discrepant IHC and ISH, borderline IM-score, het-
erogenous staining, and low-contrast staining. Of the six
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false positive cases, only two exhibited true discrepancy
between IHC and ISH after review by an experienced
breast pathologist, who scored the cases as 3+ positive
in line with ImmunoMembrane while ISH was negative.
In both cases, the original pathologist had scored the
cases 2+ and the researcher 3+.
Two false positive cases showed a borderline IM score of
10 (in the scale of 0–20) which according to our cutoff value
qualifies them as positive, although they were negative by
ISH. In both cases, both the original pathologist and the re-
searcher had scored the cases 2+.
Two false positive cases were found to exhibit heter-
ogenous staining when reviewed by an experienced
breast pathologist. In these cases, some of the photomi-
crographs were classified by ImmunoMembrane in
agreement with ISH whereas a greater number of im-
ages showed a negative score, which rendered the over-
all score in disagreement with ISH. One of the cases
was scored 2+ by the original pathologist and 3+ by
the researcher whereas the other case was scored 2+
by both.
Of the six false negative cases, one was found to be dis-
crepant between IHC and ISH after review by an experienced
breast pathologist (0/1+ IHC-negative in both the pathologist
and ImmunoMembrane DIA but positive by ISH). The case
was scored 2+ by both the original pathologist and the re-
searcher. Heterogenous staining was observed in three false
negative cases. All three cases were scored 2+ by both the
original pathologist and the researcher. Two false negative
cases exhibited low-contrast staining when reviewed by an
experienced breast pathologist. Both cases were scored 2+
by the original pathologist and the researcher.
ImmunoMembrane analysis using digital
photomicrographs and whole-slide images
Table 3 presents a cross tabulation of HER2 IHC scores ren-
dered by a pathologist with the help of ImmunoMembrane using
digital photomicrographs and by the researcher using
ImmunoMembrane directly on scanned whole-slide images.
Of the total 30 cases, two were discordant, the first having been
scored 2+ using ImmunoMembranewith photomicrographs and
3+ using WSI and the second vice versa (3+ using WSI and 2+
using photomicrographs). Interobserver variability, calculated
using linearly weighted kappa statistic, was almost perfect at
0.92 (95 % confidence interval 0.82–1.0). Figure 2 shows
ImmunoMembrane being used directly in a WSI viewer.
Discussion
In this study we, show that ImmunoMembrane [16], a free and
publicly available cross-platform compatible ImageJ plug-in
and web application for digital image analysis of HER2 IHC
(http://jvsmicroscope.uta.fi/immunomembrane/), can assist in
interpreting the status of cases visually classified as equivocal
(2+). In our material of 750 surgical resection specimens, the
proportion of immunohistochemical cases classified as
equivocal by the original pathologist was 34 % (255 cases),
which is on the upper end of the range reported in the
literature. In a systematic review from 2007, the mean
frequency of an equivocal IHC score in 17 studies was 23.3 %
(with a range of 2 to 87.5 %) [26]. In another systematic review
from 2009, the mean frequency of an equivocal IHC score in 10
studies was 18.9 % with a range of 7.9 to 53.2 % [27].
Table 1 Frequencies of the
HER2 IHC scores in percent,
number of cases in parentheses;
total number of cases 750
Pathologist visual score Researcher visual score ImmunoMembrane DIA score
Negative (0/1+) 57.6 (432) 46.8 (351) 80.8 (606)
Equivocal (2+) 34 (255) 43.7 (328) 10.1 (76)
Positive (3+) 8.4 (63) 9.5 (71) 9.1 (68)
Total 100 (750) 100 (750) 100 (750)
DIA digital image analysis
Table 2 Cross tabulation
comparing HER2 ISH (presence/
absence of amplification) with the




Pathologist visual IHC Researcher visual IHC ImmunoMembrane DIA IHC Total
0/1+ 2+ 3+ 0/1+ 2+ 3+ 0/1+ 2+ 3+
No ISH 427 5 4 322 110 4 424 7 5 436
ISH− 5 235 0 29 203 8 176 58 6 240
ISH+ 0 15 59 0 15 59 6 11 57 74
Total 432 255 63 351 328 71 606 76 68 750
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The proportion of equivocal results of 34 % (255) by the
original pathologist was reduced to 10.1 % (76 cases) by
ImmunoMembrane DIA. Of the 255 cases originally classified
as equivocal, ImmunoMembrane was able to resolve 190
(74.5 %), 10 of which emerged as positive (3+) and 180 as
negative (0/1+). In the ImmunoMembrane analysis, 65 cases
remained equivocal, while ImmunoMembrane scored five and
six cases as equivocal, originally scored as 3+ and 0/1+, respec-
tively. These data are in line with previous findings of image
analysis reducing the proportion of equivocal scores in HER2
immunohistochemistry [15, 20, 28, 29] although there have
been opposite findings also, with image analysis increasing the
proportion of equivocal results [30, 31]. Images of the result of
ImmunoMembrane DIA, demonstrating its discriminative pow-
er in cases originally classified as equivocal, are presented in
Fig. 1.
In the two-step testing algorithm proposed in theASCO/CAP
guidelines, in which an equivocal result by IHC requires addi-
tional confirmation by a validated assay for HER2 gene ampli-
fication, a reduction of the proportion of equivocal cases both
increases the information value of IHC and improves the cost-
and time-effectiveness of the testing.
Because of the substantial clinical, economic and safety im-
plications of anti-HER2 therapy, assessment of the HER2 status
of a tumour must be accurate and reproducible [6, 7]. In our
study, we used ISH as the referencemethod and defined six false
positive (3+ IHC-positive and ISH-negative) and six false neg-
ative cases (0/1+ IHC-negative and ISH-positive) in the
ImmunoMembrane analysis. ISH data was available for
41.9 % of the cases (314/750) because of the laboratory practice
of subjecting only immunohistochemically equivocal (2+) and
positive (3+) cases for ISH. The frequency of both false positive
and false negative cases was thus 1.9% (6/314) of the cases with
ISH data.
After carrying out the present study the laboratory reflex
tested for a period of time (8 months, 1 October 2014 through
31 May 2015) all IHC cases (including IHC 0/1+) by ISH (P.
Fig. 1 a–c Three result images from ImmunoMembrane digital image
analysis using photomicrographs. All three cases were originally scored
as equivocal (2+) by a pathologist. The first image (a) receives an IM
score of 2 points and is thus classified as negative (0/1+), the second
image (b) 8 points (classified as equivocal, 2+) and the third image (c)
16 points (classified as positive, 3+). The first two cases were classified
visually as 2+ by the researcher and the last one 3+. The first two cases are
negative by ISH and the last one positive
Table 3 Cross tabulation comparing ImmunoMembrane digital image





0/1+ 2+ 3+ Total
0/1+ 10 0 0 10
2+ 0 9 1 10
3+ 0 1 9 10
Total 10 10 10 30
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Heikkilä, personal communication, 11 September 2015). In
this set of 750 cases, 400 (53.3 %) were scored IHC 0/1+.
Only two cases were found positive by ISH. Such a low false
negative rate suggests that the proportion of false negatives in
our study would not have been substantially affected if the
ISH testing had included also the IHC-negative 0/1+ cases.
We analysed one of the two false negative cases by
ImmunoMembrane DIA and the result was 0/1+, in concor-
dance with the original pathologist score.
The false positive cases by ImmunoMembrane DIAwould
not have affected anti-HER2 treatment eligibility of the patients
because all IHC 2–3+ cases were subjected for ISH. The false
negative cases would have made six patients ineligible for anti-
HER2 treatment. The false negative rate of 1.9 % is neverthe-
less lower than the corresponding rate of 6 % reported for an
FDA-approved system [29]. It is also lower than the pooled
false negative rate of 11 % recently reported for visual scoring,
using approved and validated in vitro diagnostic tests in a Nor-
dic IHC quality control programme [32]. However, given the
far-reaching clinical and economic consequences of inaccurate
HER2 testing [32], even low false negative rates should not be
neglected. In the current study, ImmunoMembrane was oper-
ated by a researcher; however, as stated in the ASCO/CAP
guidelines, in clinical practice, a pathologist must confirm the
image analysis result [10].
Discrepancy between IHC analysed by ImmunoMembrane
and ISH can be due to several factors. In addition to inaccuracy
in the ImmunoMembrane analysis, the analysed images might
not be representative of the whole tumour, ISH might not be
100% accurate either, and regarding false negative cases, some
immunohistochemically negative tumours might exhibit HER2
amplification, as is well documented [26, 27, 33]. A borderline
score obtained with ImmunoMembrane DIA should be
interpreted with care by a pathologist. Heterogenous staining
has recently been shown to play a role in discordances between
pathologists in reading of HER2 IHC and can also affect the
result of ImmunoMembrane image analysis [34]. We propose
to analyse a large enough number of image fields to be sure to
representatively cover all staining patterns of the specimen in
cases with heterogenous staining. This approach is in line with
what is recommended in the literature for ISH [35]. Low-
contrast staining which can be due to the tissue section proper-
ties can influence ImmunoMembrane DIA even with on-slide
control tissues.
Our material consisted of a sample of surgical resection
specimens from a large university hospital pathology depart-
ment, reflecting the daily work of diagnostic pathologists. We
analysed whole sections instead of tissue microarrays or core
needle biopsies in order to mimic, as closely as possible, the
daily diagnostic setting. The rate of ISH-positive cases was
somewhat low in our material, which can be explained by sam-
pling error due to cases missing from the archives at the time of
retrieval. The rate of ISH-positive cases in the original database
search is in line with recent findings in the literature [1–4].
As described earlier [16], ImmunoMembrane is a software
application for semi-quantitative classification of HER2 IHC,
designed as a diagnostic aid for the trained pathologist.
ImmunoMembrane does not offer true quantitation of the
IHC stain (or ultimately of the amount of HER2 protein),
which, in the case of diaminobenzidine (DAB)-based detec-
tion systems widely used in HER2 IHC assays, may prove
difficult due to the physical properties of the chromogen [36,
37]. ImmunoMembrane performs object-based image analysis
[38] by separating the objects of interest (segmenting DAB-
stained cell membranes) from the background and analysing
them with regard to completeness and intensity of the staining
reaction. ImmunoMembrane thus mimics the visual interpre-
tation of HER2 IHC as defined in clinical guidelines and was
initially pre-calibrated to match the visual scoring of an expert
pathologist. While the image analysis algorithm itself is auto-
mated, the selection of regions of interest (ROI) has to be done
visually, preferably by a pathologist.
Fig. 2 a–b Two screenshots demonstrating the process of using
ImmunoMembrane digital image analysis directly while viewing a
whole-slide image (a). The region of interest is demarcated with a
polygon drawing tool. After the analysis is complete, a pseudo-coloured
result image is shown on top of the whole-slide image indicating
complete and strong membrane staining in red and incomplete or weak
staining in green (b). The depicted tissue exhibits positive 3+ staining
according to ImmunoMembrane image analysis
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In conclusion, the accuracy of HER2 IHC can be improved
in equivocal cases by the use of digital image analysis carried
out by the ImmunoMembrane software. In our material, al-
most three out of four cases originally classified as equivocal
by a pathologist were further classified into either negative or
positive without loss of accuracy. ImmunoMembrane is easy
to apply in clinical practice by virtue of its usability with
various combinations of imaging equipment (microscope
and camera) and the possibility to use it over the internet
(without software download or installation). The fact that the
source code of the software is open adds to its utility in the
research setting [39, 40].
A new way to integrate ImmunoMembrane into routine
diagnostics comes with the increasing use of whole-slide scan-
ners. When HER2 IHC slides are scanned as whole-slide im-
ages, pathologists need not spend time acquiring photomicro-
graphs from the microscope. Defining analysable regions of
interest in the WSI viewer is fast and yields almost perfect
agreement compared with photomicrographs. This is in line
with the general finding of good to superior agreement be-
tween glass slide and digital slide diagnoses [41] as well as
the specific finding of equivalent results in the interpretation
of HER2 IHC when using glass slides and whole-slide images
[42]. In summary, digital image analysis such as that of HER2
offers a functionality that conventional work with glass slides
does not have. The routine use of digital image analysis on
whole-slide images offers the pathologist an enhanced diag-
nostic tool.
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